Collagen is not just a moisturiser ingredient: how skin actually builds it and what helps

How skin synthesises collagen: the fibroblast pathway

Collagen in the dermis is synthesised exclusively by fibroblasts — specialised cells that produce both the collagen protein chains and the enzymes that weave them into the triple-helix fibres that give skin its structural tensile strength. The synthesis process requires several converging inputs: the transcription of procollagen type 1 genes (stimulated by growth factors including TGF-β1, IGF-1 and retinoid-activated nuclear receptors), adequate amino acid substrates (specifically glycine, proline and hydroxyproline), vitamin C as the cofactor for the prolyl hydroxylase enzyme that adds the hydroxyl groups that stabilise the triple helix, copper as the cofactor for lysyl oxidase that cross-links adjacent collagen fibres into functional structural units, and the fibroblast activity level that determines how many of the above inputs are actually used. Most topical "collagen" ingredients fail to increase skin collagen because they provide an ingredient that sits on the surface rather than influencing any of these fibroblast-level synthesis inputs.

Why topical collagen does not become dermal collagen

The collagen molecule is a triple helix with a molecular weight of approximately 285,000 daltons — far too large to penetrate the stratum corneum, which has an effective permeability threshold of approximately 500 daltons for simple diffusion. When collagen is applied to the skin in a cream or serum, it remains on the stratum corneum surface as a film-forming hydrating agent, where it provides a moisturising effect through water-retention rather than any structural contribution to the dermal collagen matrix. Hydrolysed collagen (broken into smaller peptides) has better skin penetration, and low-molecular hydrolysed collagen (molecular weight below 3,000 daltons) penetrates to the upper dermis where fibroblasts are located. Once there, collagen peptides act as matrikine signals — fragments that mimic the breakdown products of existing collagen and therefore activate the fibroblast's damage-response programme to synthesise new collagen. This is why low-molecular collagen in an ampoule (combined with a retinol that amplifies the same programme) produces more measurable collagen stimulation than a cream with decorative full-size collagen at the top of the ingredient list.

Retinol as the validated collagen preservation and stimulation active

Retinol's effect on collagen is one of the most extensively documented mechanisms in dermatological research. It operates through two pathways: first, it inhibits AP-1-driven transcription of MMP-1 (the collagenase enzyme that degrades existing collagen), reducing the rate of collagen breakdown independent of UV exposure; second, it activates RAR nuclear receptors in fibroblasts and keratinocytes to increase procollagen type 1 gene expression, stimulating new collagen synthesis. The combination of preserved existing collagen and increased new collagen synthesis produces the progressive improvement in skin firmness and fine line reduction that clinical retinol studies consistently demonstrate over twelve to twenty-four weeks of use. For retinol to work optimally, the vitamin A must be converted by keratinocytes to retinaldehyde and then to retinoic acid — the active form. Product stability (retinol oxidises rapidly in air and light exposure) and the encapsulation technology used determine how much unconverted retinol survives to reach the skin and how much is available for this conversion.

How the turnover active cream completes the collagen-building sequence

A collagen-stimulating cream applied as the sealant step over retinol and PDRN ampoules provides the physical environment for overnight collagen synthesis: the occlusive and emollient base prevents TEWL that would undermine the barrier repair concurrent with collagen stimulation, while the PDRN in the cream formula provides a second-dose adenosine receptor activation at a lower concentration than the dedicated PDRN ampoule. The cream format has a longer dwell time on the skin than the ampoule — the emollient carriers in the cream reduce the active ingredient's evaporation rate, extending the contact time between the PDRN and its target receptors through the night. Applied after the retinol ampoule (not before, to avoid sequestration of the retinol in the cream's emollient matrix), the turnover active cream serves as both the moisture seal and a sustained-release PDRN delivery extension.

Vitamin C and copper: the cofactors the synthesis process cannot proceed without

Vitamin C and copper serve as essential cofactors at different steps in the collagen synthesis cascade — not as initiating signals but as rate-limiting substrates without which enzymatic steps cannot proceed regardless of how much fibroblast activation is occurring. Prolyl hydroxylase (which hydroxylates proline residues to enable triple-helix formation) requires vitamin C as a co-substrate; without adequate intracellular vitamin C, collagen chains fold incorrectly and are degraded before assembly. Lysyl oxidase (which cross-links adjacent collagen molecules into the structural fibres that provide tensile strength) requires copper as a cofactor; without copper, newly synthesised collagen remains as insufficiently cross-linked individual chains that provide far less structural strength than properly cross-linked fibres. Including a morning vitamin C serum and ensuring dietary copper adequacy (from nuts, shellfish and legumes) addresses both cofactor needs alongside the fibroblast-stimulating actives.